Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24508284 | 0.95 | SIGMAR1 (0.44) | SIGMAR1DRD2DRD1DRD3DRD5 | |
| SCHEMBL23568558 | 0.89 | SIGMAR1 (0.44) | SIGMAR1DRD2DRD1DRD3HRH3 | |
| SCHEMBL22856533 | 0.88 | SIGMAR1 (0.43) | SIGMAR1DRD2DRD1DRD3HRH3 | |
| SCHEMBL25702127 | 0.86 | SIGMAR1 (0.41) | SIGMAR1DRD2DRD1DRD3HRH3 | |
| SCHEMBL23560057 | 0.85 | SIGMAR1 (0.44) | SIGMAR1DRD2DRD1DRD3HRH3 | |
| SCHEMBL23696422 | 0.84 | SIGMAR1 (0.45) | SIGMAR1DRD2DRD1DRD3DRD5 | |
| SCHEMBL23696449 | 0.84 | SIGMAR1 (0.43) | SIGMAR1DRD2DRD1DRD3HRH3 | |
| SCHEMBL22856124 | 0.82 | SIGMAR1 (0.45) | SIGMAR1DRD2DRD1DRD3DRD5 | |
| SCHEMBL23572262 | 0.79 | SIGMAR1 (0.39) | SIGMAR1DRD2DRD1DRD3DRD5 | |
| SCHEMBL23696429 | 0.79 | SIGMAR1 (0.44) | SIGMAR1DRD2DRD1DRD3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SIGMAR1 3199/4885DRD2 4346/4885DRD1 4393/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SIGMAR1 3199/4885DRD2 4346/4885DRD1 4393/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SIGMAR1 3199/4885DRD2 4346/4885DRD1 4393/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SIGMAR1 3199/4885DRD2 4346/4885DRD1 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.